 Immunogenic cell death, ICD, is a novel form of regulated cell death, RCD, that can trigger an immune response against cancer cells. It involves the release of danger-associated molecular patterns, damps, from dying tumor cells, which activate the immune system to recognize and eliminate the remaining cancer cells. Research suggests that ICD may be used as a therapeutic strategy for treating hematologic malignancies. This article was authored by Jiaoyun Liu, Shintong Su, Caning Liu, and others.